Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Epidemiology

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental condition defined by persistent patterns of inattention, hyperactivity and impulsivity that interfere with daily functioning. Diagnostic frameworks such as DSM-5 and ICD-11 emphasise symptom clusters and require evidence of impairment across multiple settings, often supported by structured interviews and rating scales. A strong heritable component—estimated at around 70–80%—combines with environmental influences, including prenatal exposures, to shape individual risk. First-line treatments encompass stimulant medications (methylphenidate and amphetamines) and non-pharmacological approaches such as behavioural therapy and cognitive training. Recent advances have explored digital and integrative interventions alongside improved algorithms for personalised care. Epidemiological studies track a global prevalence of approximately 5% in children and 2–3% in adults, with notable increases over the past two decades that reflect heightened recognition, changing diagnostic practices and potential environmental trends. The disorder’s worldwide significance lies in its impact on educational attainment, occupational outcomes and comorbid mental health conditions, driving ongoing efforts to refine screening, optimise treatment pathways and understand long-term trajectories.

Research from Nature Portfolio

A large multinational cohort study encompassing over 3.6 million mother–child pairs across seven countries assessed the link between maternal diabetes and offspring ADHD risk. By applying time-to-event analysis, researchers found a modest increase in ADHD incidence among children exposed in utero to gestational and pregestational diabetes, although sibling comparisons suggested shared familial factors may account for much of this association. These findings prompt reevaluation of hyperglycaemia’s causal role and highlight the importance of controlling for genetic and environmental confounders in prenatal risk research.

Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Epidemiology publication trend

The graph below shows the total number of articles in attention-deficit/hyperactivity disorder: diagnosis, treatment, and epidemiology across all publications each year (not limited to Nature Index journals).

Technical terms

Hazard ratio: A measure of how often a particular event occurs in one group compared to another over time in cohort studies.

Gestational diabetes mellitus (GDM): Elevated blood glucose first recognised during pregnancy, which may influence neurodevelopmental outcomes.

Network meta-analysis: A statistical approach that compares multiple interventions simultaneously by combining direct and indirect evidence.

Polygenic component: The combined effect of many genetic variants, each of small individual impact, contributing to overall disease risk.

Behavioural therapy: A non-pharmacological intervention that uses structured techniques to modify maladaptive behaviours and improve executive functioning.

References

1. Maternal diabetes and risk of attention-deficit/hyperactivity disorder in offspring in a multinational cohort of 3.6 million mother–child pairs. Nature Medicine (2024).
2. Enhancing attention in children using an integrated cognitive-physical videogame: A pilot study. npj Digital Medicine (2023).
3. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry (2018).
4. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PLOS ONE (2017).